Author:
Diaz Z,Laurenzana A,Mann K K,Bismar T A,Schipper H M,Miller W H
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference50 articles.
1. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345–3353.
2. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360.
3. Tallman MS . Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 2004; 41: 27–32.
4. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S . Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893–3903.
5. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93: 278–283.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献